Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification

被引:2
|
作者
Feng, Lijuan [1 ]
Kan, Ying [1 ]
Wang, Wei [1 ]
Wang, Chao [2 ]
Zhang, Hui [3 ]
Xie, Peng [4 ]
Yang, Jigang [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, 95 Yong Rd, Beijing 100050, Peoples R China
[2] SinoUn Healthcare Inc, Beijing 100192, Peoples R China
[3] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China
[4] Hebei Med Univ, Hosp 3, Dept Nucl Med, Shijiazhuang 050051, Peoples R China
关键词
Event-free survival; Neuroblastoma; Nomogram; Overall survival; Prognosis; MITOSIS-KARYORRHEXIS INDEX; CLASSIFICATION;
D O I
10.1007/s00432-023-05398-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo develop and validate a nomogram for predicting survival in intermediate- and high-risk neuroblastoma patients and to compare the accuracy of the nomogram in predicting survival with Children's Oncology Group (COG) risk stratification.MethodsA total of 885 intermediate- and high-risk neuroblastoma patients were enrolled in this study, including 243 patients from our hospital (the training set) and 642 patients from the TARGET database (the validation set). The factors related to event-free survival (EFS) and overall survival (OS) in neuroblastoma were determined to construct the nomogram by Cox regression analysis. The C-index, calibration curves, and area under the time-dependent receiver operating characteristic curves (AUCs) were used to assess the predictive performance of the nomogram.ResultsInternational Neuroblastoma Staging System stage and Mitosis-karyorrhexis index (MKI) were significant unfavorable factors for EFS, while MKI and MYCN status were significant unfavorable factors for OS. The C-index of the nomogram was 0.621 and 0.586 for predicting EFS, 0.650 and 0.570 for predicting OS in the training and validation sets, respectively. The calibration curves revealed good agreement in the EFS and OS predicted by the nomogram. The AUCs of the nomogram for 1-, 2-, 3-year EFS and OS were 0.633, 0.669, 0.604 and 0.672, 0.670, 0.702 in the training set, respectively. Moreover, the nomogram was able to classify patients into two groups according to risk scores, with the "high-risk" group having a lower survival rate than the "intermediate-risk" group. And the nomogram performed better than the COG risk stratification, which had a C-index of 0.537, 0.502 and 0.565, 0.572 for predicting EFS, OS in the training and validation sets, respectively.ConclusionWe developed and validated a prognostic nomogram for intermediate- and high-risk neuroblastoma patients that clinicians can use to make more informed decisions for individual patients.
引用
收藏
页码:16377 / 16390
页数:14
相关论文
共 50 条
  • [1] Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification
    Lijuan Feng
    Ying Kan
    Wei Wang
    Chao Wang
    Hui Zhang
    Peng Xie
    Jigang Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16377 - 16390
  • [2] A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma
    Sun, Quan
    Chen, Yanmin
    Jin, Qianya
    Yuan, Xiaojun
    EUROPEAN JOURNAL OF PEDIATRICS, 2022, 181 (12) : 4135 - 4147
  • [3] A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma
    Quan Sun
    Yanmin Chen
    Qianya Jin
    Xiaojun Yuan
    European Journal of Pediatrics, 2022, 181 : 4135 - 4147
  • [4] Development and validation of a lung metastases-predicting nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
    Ma, Wenhui
    Yu, Feng
    Chen, Bowen
    Yang, Zhiping
    Kang, Fei
    Li, Xiang
    Yang, Weidong
    Wang, Jing
    FUTURE ONCOLOGY, 2024, 20 (22) : 1575 - 1586
  • [5] A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project
    Moreno, Lucas
    Guo, Dongjing
    Irwin, Meredith S.
    Berthold, Frank
    Hogarty, Michael
    Kamijo, Takehiko
    Morgenstern, Daniel
    Pasqualini, Claudia
    Ash, Shifra
    Potschger, Ulrike
    Ladenstein, Ruth
    Valteau-Couanet, Dominique
    Cohn, Susan L.
    Pearson, Andrew D. J.
    London, Wendy B.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (03)
  • [6] Development and validation of a novel nomogram for predicting overall survival patients with neuroblastoma
    Zhao, Jin-du
    Lu, Xian-ying
    Chen, Tian -ping
    Duan, Xian-Lun
    Zuo, Wei
    Sai, Kai
    Zhu, Li -ran
    Gao, Qun
    EJSO, 2024, 50 (06):
  • [7] Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma
    Balyasny, Skye
    Lee, Sang Mee
    Desai, Ami V.
    Volchenboum, Samuel L.
    Naranjo, Arlene
    Park, Julie R.
    London, Wendy B.
    Cohn, Susan L.
    Applebaum, Mark A.
    JAMA NETWORK OPEN, 2021, 4 (07)
  • [8] Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)
    Pinto, Navin
    Naranjo, Arlene
    Hibbitts, Emily
    Kreissman, Susan G.
    Granger, M. Meaghan
    Irwin, Meredith S.
    Bagatell, Rochelle
    London, Wendy B.
    Greengard, Emily G.
    Park, Julie R.
    Dubois, Steven G.
    EUROPEAN JOURNAL OF CANCER, 2019, 112 : 66 - 79
  • [9] Needle core vs open biopsy for diagnosis of intermediate- and high-risk neuroblastoma in children
    Hassan, Saif F.
    Mathur, Shawn
    Magliaro, Thomas J.
    Larimer, Emily L.
    Ferrell, Lauren B.
    Vasudevan, Sanjeev A.
    Patterson, Danielle M.
    Louis, Chrystal U.
    Russell, Heidi V.
    Nuchtern, Jed G.
    Kim, Eugene S.
    JOURNAL OF PEDIATRIC SURGERY, 2012, 47 (06) : 1261 - 1266
  • [10] The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
    London, WB
    Boni, L
    Simon, T
    Berthold, F
    Twist, C
    Schmidt, ML
    Castleberry, RP
    Matthay, KK
    Cohn, SL
    De Bernardi, B
    CANCER LETTERS, 2005, 228 (1-2) : 257 - 266